The majority of patients with epithelial ovarian cancer currently receive anti-angiogenic treatment in addition to platinum-based chemotherapy, frequently with the humanized anti-VEGF antibody bevacizumab. This evidence concerns the gene VEGFA and ovarian carcinoma.